

List Of Publications:

1. **Juneja, P.**, Tripathi, D. M., & Kaur, S. (2022). Revisiting the gut-liver axis: Gut lymphatic system in liver cirrhosis and portal hypertension. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 322(5), G473-G479.
2. **Juneja, P.**, Rahman, S. N. R., Jakhar, D., Mourya, A. K., Tripathi, D. M., Kaur, I., ... & Kaur, S. (2023). Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis. *JHEP Reports*, 100816.
3. **Juneja, P.**, Sharma, A., Shasthry, S. M., Kumar, G., Tripathi, D. M., Rajan, V., ... & Kaur, S. (2023). Podoplanin-positive dilated lymphatic vessels in duodenum associates with three-month mortality in patients with cirrhosis. *Frontiers in Physiology*, 14, 1045983.
4. Biswas, S., Yadav, N., **Juneja, P.**, Mourya, A. K., Kaur, S., Tripathi, D. M., & Chauhan, V. S. (2022). Conformationally Restricted Dipeptide-Based Nanoparticles for Delivery of siRNA in Experimental Liver Cirrhosis. *ACS omega*, 7(41), 36811-36824.
5. Tripathi, D. M., Rohilla, S., Kaur, I., Siddiqui, H., Rawal, P., **Juneja, P.**, ... & Kaur, S. (2021). Immunonano-lipocarrier-mediated liver sinusoidal endothelial cell-specific RUNX1 inhibition impedes immune cell infiltration and hepatic inflammation in murine model of NASH. *International Journal of Molecular Sciences*, 22(16), 8489.
6. Sharma, R. K., Singh, M., Ghimeray, K., **Juneja, P.**, Dev, G., Pulavarthi, S., ... & Akundi, R. S. (2021). Imidazopyridazine acetylcholinesterase inhibitors display potent anti-proliferative effects in the human neuroblastoma cell-line, IMR-32. *Molecules*, 26(17), 5319.